The IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective longitudinal study designed to enroll 1000 hospitalized patients with COVID-19 (NCT04378777). IMPACC collects detailed clinical, laboratory and radiographic data along with longitudinal biologic sampling of blood and respiratory secretions for in depth testing. Clinical and lab data are integrated to identify immunologic, virologic, proteomic, metabolomic and genomic features of COVID-19-related susceptibility, severity and disease progression. The goals of IMPACC are to better understand the contributions of pathogen dynamics and host immune responses to the severity and course of COVID-19 and to generate hypotheses for identification of biomarkers and effective therapeutics, including optimal timing of such interventions. In this report we summarize the IMPACC study design and protocols including clinical criteria and recruitment, multi-site standardized sample collection and processing, virologic and immunologic assays, harmonization of assay protocols, high-level analyses and the data sharing plans.

COVID-19 队列中的 IMmunoPhenotyping 评估 (IMPACC) 是一项前瞻性纵向研究，旨在招募 1000 名住院的 COVID-19 患者 (NCT04378777)。 IMPACC 收集详细的临床、实验室和放射学数据以及血液和呼吸道分泌物的纵向生物采样，以进行深入测试。整合临床和实验室数据，以确定与 COVID-19 相关的易感性、严重程度和疾病进展的免疫学、病毒学、蛋白质组学、代谢组学和基因组学特征。 IMPACC 的目标是更好地了解病原体动态和宿主免疫反应对 COVID-19 严重程度和病程的影响，并提出用于识别生物标志物和有效治疗方法的假设，包括此类干预措施的最佳时机。在本报告中，我们总结了 IMPACC 研究设计和方案，包括临床标准和招募、多中心标准化样本采集和处理、病毒学和免疫学测定、测定方案的协调、高水平分析和数据共享计划。